To evaluate the outcomes of adult patients with spermatic cord sarcoma (SCS).
All consecutive patients with SCS managed by the French Sarcoma Group from 1980 to 2017 were analysed retrospectively. Multivariate analysis (MVA) was used to identify independent correlates of overall survival (OS), metastasis-free survival (MFS), and local relapse-free survival (LRFS).
A total of 224 patients were recorded. The median age was 65.1 years. Forty-one (20.1%) SCSs were discovered unexpectedly during inguinal hernia surgery. The most common subtypes were liposarcoma (LPS) (73%) and leiomyosarcoma (LMS) (12.5%). The initial treatment was surgery for 218 (97.3%) patients. Forty-two patients (18.8%) received radiotherapy, 17 patients (7.6%) received chemotherapy. The median follow-up was 5.1 years. The median OS was 13.9 years. In MVA, OS decreased significantly with histology (HR, well-differentiated LPS versus others = 0.096; p = 0.0224), high grade (HR, 3 versus 1–2 = 2.7; p = 0.0111), previous cancer and metastasis at diagnosis (HR = 6.8; p = 0.0006). The five-year MFS was 85.9% [95% CI: 79.3–90.6]. In MVA, significant factors associated with MFS were LMS subtype (HR = 4.517; p < 10-4) and grade 3 (HR = 3.664; p < 10-3). The five-year LRFS survival rate was 67.9% [95% CI: 59.6–74.9]. In MVA, significant factors associated with local relapse were margins and wide reresection (WRR) after incomplete resection. OS was not significantly different between patients with initial R0/R1 resection and R2 patients who underwent WRR.
Unplanned surgery affected 20.1% of SCSs. A nonreducible painless inguinal lump should suggest a sarcoma. WRR with R0 resection achieved similar OS to patients with correct surgery upfront.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Surgical Oncology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Spermatic cord sarcoma in adults.J Urol. 1978; 120: 301-305
- Paratesticular liposarcoma masquerading as an inguinal hernia.Urology. 2018; 113: e5-e6
- Liposarcoma in the spermatic cord presenting as an inguinal swelling.Transl Androl Urol. 2017; 6: 978-980
- Paratesticular soft-tissue masses in orchiectomy specimens: a 17-year survey of primary and incidental cases from one institution.Int J Surg Pathol. 2017; 25: 480-487
- Sarcomas of the spermatic cord and para-testicular tissues: our experience and review of current literature.British Journal of Medical and Surgical Urology. 2012; 5: 271-278
- Current management of liposarcoma of the spermatic cord: a case report and review of the literature.Mol Clin Oncol. mars. 2017; 6: 438-440
- Adult inguinoscrotal sarcomas: outcome analysis of 21 cases, systematic review of the literature and meta-analysis.World J Urol. 1 avr. 2014; 32: 445-451
- Adult spermatic cord sarcomas: management and results.Ann Surg Oncol. 1 juill. 2003; 10: 669-675
- Prognostic factors and outcome of spermatic cord sarcoma.Ann Surg Oncol. 2014 Oct; 21: 3557-3563
- Importance of wide re-resection in adult spermatic cord sarcomas: report on oncologic outcomes at a single institution.J Surg Oncol. 2018 Jun; 117: 1464-1468
- Liposarcoma of the spermatic cord: impact of final surgical intervention- an institutional experience.Int J Surg Oncol. 2016; 20164785394
- Primary spermatic cord tumors: disease characteristics, prognostic factors, and treatment outcomes.Urol Oncol: Seminars and Original Investigations. 1 janv. 2014; 32: 52.e19-52.e25
- Spermatic cord sarcoma: outcome, patterns of failure and management.J Urol. 2001; 166: 1306-1310
- Safety and efficacy of intensity-modulated radiotherapy in the management of spermatic cord sarcoma.Cancer/Radiothérapie. févr. 2017; 21: 16-20
- WHO classification of tumours of soft tissue and bone.in: WHO classification of tumours of soft tissue and bone. 4th éd. IARC Press, Lyon, France2013 ([WHO)])
- Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system.Int J Cancer. 1984; 33: 37-42
- Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2021 Nov; 32: 1348-1365
- Adult paratesticular sarcomas: a review of 21 cases.The J Urol 1 août. 1991; 146 (Part 1)): 342-345
- Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group.Ann Oncol. 1 mars. 2014; 25: 735-742
- Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative RPS working Group.Ann Surg mai. 2016; 263: 1002-1009
- Watch and wait approach for Re-excision after unplanned yet macroscopically complete excision of extremity and superficial truncal soft tissue sarcoma is safe and does not affect metastatic risk or amputation rate.Ann Surg Oncol. oct 2019; 26: 3526-3534
- The management of spermatic cord sarcoma.Cancer. 1 mai. 1996; 77: 1873-1876
- Paratesticular liposarcoma: unusual patterns of recurrence and importance of margins.Ann Surg Oncol. 1 juill. 2013; 20: 2148-2155
- Al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control.J Clin Oncol janv. 2009; 27: 31-37
- Imaging strategy for detecting lung metastases at presentation in patients with soft tissue sarcomas.Eur J Cancer. 2008; 44: 1841-1845
- Treatment of children with non metastatic paratesticular rhabdomyosarcoma: results of the malignant mesenchymal tumors studies (MMT 84 and MMT 89) of the international society of pediatric oncology.J Clin Outcome Manag. 2003; 21: 793-798
Published online: February 25, 2023
Accepted: February 22, 2023
Received in revised form: February 10, 2023
Received: January 20, 2023
Publication stageIn Press Journal Pre-Proof
© 2023 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.